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In 2014, UNAIDS published “90-90-90: An ambitious treatment target to help end the AIDS 
epidemic”, in which goals for HIV testing, initiation and treatment are described. Briefly, the goals 
are for 90% of all people living with HIV to know their HIV status, 90% of all people diagnosed with 
HIV to receive sustained antiretroviral treatment (ART) and 90% of all people receiving ART to have 
achieved viral suppression. 
Since these targets were published, many studies have assessed progress towards them in different 
settings. Studies reporting on the third 90 are described and synthesised in the Literature Review 
(Part B). We found significant heterogeneity in data sources, outcome definitions, methods and 
results across different studies, and we highlighted important themes and identified further research 
that is required. 
The Khayelitsha Cohort in Cape Town is one of the oldest and largest HIV cohorts in South Africa, 
where ART was initially rolled out in partnership with Médecins Sans Frontières in 2001. With about 
22 000 patients on ART and in care in the cohort in 2016, Khayelitsha reported almost 89% VL 
suppression on routine quarterly reports, but also reported 56% recorded completion of VL tests. 
This low reported completion did not necessarily imply low actual completion, but it did raise 
questions about the validity of the reported suppression proportion and about the reasons for low 
reported completion. A series of steps must be completed for a VL test result to be included in 
routine data and thus contribute to the suppression and completion proportions reported. Among 
those in whom a VL is expected, a blood sample must be collected and tested, the result must be 
filed in the folder, noted by the clinician and captured electronically. We call this the “VL cascade”. 
In order to address these questions about suppression and completion, a retrospective cohort was 
constructed including all patients on ART and in care at provincial healthcare facilities in Khayelitsha 
with a routine VL expected in the year from 1 July 2015 to 30 June 2016. The Protocol (Part A) was 
granted ethical approval by the University of Cape Town Human Research Ethics Committee. 
We used 3 data sources to assess completion at each step in the VL cascade. Electronic data were 
requested from the Primary Healthcare Information System (PHCIS), which contains routine data 
digitised from the physical folder by clerks working on-site at healthcare facilities, and the Provincial 
Health Data Centre (PHDC), which contains data on all laboratory tests done in Khayelitsha. We 
manually reviewed 1 035 physical patient folders. 
The suppression proportion at various thresholds was calculated a) using only data digitised into 
PHCIS and b) using all data from the PHDC, and these proportions were compared. Logistic 
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regression was used to determine factors associated with the outcomes of a) VL tests being done 
and b) VL tests completing the VL cascade to be included in routine reports. Healthcare facility was 
included in the model, as well as age category and pregnancy status, as different models of care are 
provided for children and pregnant women in Khayelitsha. 
The results of the study are reported in the Manuscript (Part C). Of 22 991 patients with a routine VL 
due, 84% were done, 79% filed, 76% noted, and 55% captured. Using all laboratory data, VL 
suppression was estimated to be 82%, 87%, 89% and 91% at the 50, 200, 400 and 1 000 copies/mL 
thresholds respectively, but reported suppression using captured results would have been 80%, 86%, 
88% and 89% at those thresholds. Routine VL were more likely to be done among children <15 years 
old (aOR 1.89, 95%CI 1.45–2.48) and pregnant women (aOR 1.90, 95%CI 1.28–2.81) compared to 
adult men, adjusted for facility. 
We concluded that, despite low reported completion, actual VL testing completion was high. 
Reported suppression in routine data was very similar to suppression calculated using all laboratory 
data, thus providing an accurate measure of progress towards the third 90-90-90 target. More work 
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PART A: Protocol 
Synopsis 
Title 
How accurately do routinely reported HIV viral load suppression proportions reflect progress 
towards the 90-90-90 target in the population on ART in Khayelitsha, South Africa? 
Primary objective 
To determine how accurately the viral load (VL) suppression proportion reported in the routine 
antiretroviral treatment (ART) programme data reflects the suppression proportion in the 
population on ART, given the low reported completion proportions. 
Secondary objective 
To identify the steps in the VL cascade that impact negatively on completion proportions and 
quantify their impact, in order to inform future interventions to improve the completion proportion. 
Sample size 
Part 1: all routine VLs expected during the study period (one year) for patients on ART and in care in 
Khayelitsha (about 22 000). 
Part 2: about 1 000 expected viral loads that were reported as not done. 
Study population 
Patients on ART and in care at provincial primary healthcare facilities in Khayelitsha. 
Study sites 
Khayelitsha (Site B) CHC, Michael Mapongwana CDC, Nolungile CDC. 
Background 
The Provincial Government of the Western Cape (PGWC) reports high viral suppression proportions 
but low completion proportions, about 90% and 60% respectively for Khayelitsha in the study 
period. Given the low completion proportion, it is unknown how representative the reported 
suppression proportion is. Furthermore, there is no evidence base on which to design interventions 
to improve completion proportions. 
The proposed study 
This study will use three data sources – the Primary Healthcare Information System (PHCIS), the 
Provincial Health Data Centre (PHDC) and physical folder review – to assess completion and 
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suppression at each step in the viral load cascade and quantify failure to progress through each step. 
The Provincial Department of Health (DoH) collects routine ART programme data and only these 
routine data elements will be used; no additional non-routine elements will be collected. Use of 
these routine data for the Khayelitsha Cohort has already been approved by the University of Cape 
Town Human Research Ethics Committee (HREC REF Number 395/2005, updated annually). 
The primary risk of this study is to patient privacy and confidentiality, and every effort to mitigate 
this risk will be taken, as detailed under “Privacy and confidentiality” in the protocol. Briefly: the 
review of folders for missing viral load results not captured electronically constitutes a data cleaning 
exercise as these results should have been captured as part of routine DoH data collection to PHCIS 
anyway. Only staff with existing approved access to these systems and these data will work on this 
study; no new access will be granted. Results of the folder review will be stored directly to an 
encrypted password-protected electronic database; no paper records will be generated. This study 
will be conducted with direct oversight from the substructure Medical Officer who will monitor 
study activities closely. As such, the risk to patient privacy and confidentiality is perceived to be 
minimal. 
Background 
In 2014, UNAIDS published “90-90-90: An ambitious treatment target to help end the AIDS 
epidemic”, in which goals for HIV testing, initiation and treatment are described.(1) Briefly, the goals 
are for 90% of all people living with HIV to know their HIV status, 90% of all people diagnosed with 
HIV to receive sustained ART and 90% of all people receiving ART to have achieved viral suppression. 
VL testing is the gold standard in HIV treatment monitoring.(2)(3)(4) The VL test used in the 
provincial ART programme measures the amount of HIV-1 genetic material in a sample of an HIV-
positive patient’s blood, reported as copies per millilitre (copies/ml). Viral suppression is the direct 
goal of ART, so VL testing provides a direct measure of treatment success. (This remains true despite 
some new calls to look beyond viral suppression to health-related quality of life; viral suppression is 
a necessary prerequisite.)(5) 
A patient is said to be virally suppressed if their VL is below a certain threshold. In South Africa, this 
threshold is 400 copies/ml, but the UNAIDS threshold for 90-90-90 is generally taken to be 1000 
copies/ml. If a patient has a high VL this indicates that treatment is not effective, usually due either 
to poor adherence (the patient is not taking their antiretroviral medication consistently) or 
resistance (the virus in this patient is no longer as susceptible to the specific combination of 
antiretroviral medication the patient is taking).(2)(6) 
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Both suppressed and unsuppressed VL results can inform patient management and clinical care. A 
suppressed VL may be used along with other indications to identify patients for recruitment to 
differentiated models of care. For example, the guidelines from the PGWC state that patients are 
eligible for recruitment to an ART adherence club if they are on ART for 6 months, have no 
comorbidities that require more frequent clinical visits and have a suppressed VL.(7) Recruitment of 
stable patients to adherence clubs is seen by many patients as beneficial to them individually as it 
decreases the frequency and duration of visits. And it is beneficial to the ART programme as it 
reduces the load on clinicians and facilities and is therefore seen as an essential part of making 
increases in ART coverage (the second 90-90-90 target) sustainable in the context of an already 
overburdened healthcare system. 
An unsuppressed VL result indicates to a clinician that the virus is replicating. A replicating virus may 
lead to a compromised immune system, drug resistance and increased risk of the patient 
transmitting the virus to others. Preventing this replication is the direct purpose of ART. If ART is not 
successfully suppressing replication then an intervention is required, usually adherence counselling 
and continued treatment followed by further testing and possibly switching of ART regimen if 
required. Failure or delay in switching patients who remain unsuppressed on their existing regimens 
has been shown to have a negative impact at the individual and programme levels. It can lead to 
increased risk of resistance,(8) opportunistic infections,(9) HIV transmission and transmission of 
resistant strains.(10) 
As stated in the Western Cape Consolidated Guidelines for HIV Treatment, one of the specific 
objectives of the Western Cape ART Programme is to “promote viral load testing as a preferred 
approach for monitoring ART success and diagnosing treatment failure”.(11) The guidelines 
recommend performing routine VL tests in all patients at four months after starting lifelong ART, 
then again at 12 months on ART and every 12 months thereafter. The guidelines have further 
recommendations for more frequent testing following a high VL, for patients on 2nd and 3rd line 
regimens, patients with comorbidities, infants, and for pregnant and breastfeeding mothers. 
The Primary Healthcare Information System (PHCIS) is a networked, central database-driven 
electronic health information system developed by the PGWC. Workstations running PHCIS are 
located in the registries at facilities where clerks electronically capture HIV programme information 
on a daily basis from the paper stationery in the patient folder to PHCIS. For monitoring and 
evaluation of routine VL testing, PHCIS calculates patient-specific windows of time around each 
expected VL test due date, based on the ART start date captured for each patient (Figure 1). These 
windows are contiguous, such that any VL taken after three months duration on ART will be counted 
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in one window or another. In other words, a patient’s 12 monthly cycle may be brought forwards or 
pushed backwards (often to align with their adherence club’s testing schedule), but as long as they 
continue to have a VL taken every 12 months then this will fulfil the minimum routine VL completion 
requirements. Using these routine VL due windows, a VL completion proportion is calculated and 
reported alongside the suppression proportion. For the reporting period of Q3 2015 to Q2 2016, the 
PGWC reported a completion proportion in Khayelitsha of 55.9% and a suppression proportion of 
89.8%. There are many plausible explanations for this low reported coverage but to date there is no 
evidence-based research to confirm or quantify the causes. 
 
Figure 1: Viral load allocation – using 24 month due date as example 
It is therefore impossible to say if VL results are missing systematically or at random, and whether or 
not the reported suppression proportion accurately reflects suppression in the population on ART. 
Furthermore, without a better understanding of the challenges to completion, it is difficult to know 
if results from these routine VL tests are available to the clinician to inform clinical assessment, and 
impossible to initiate targeted, evidence-based interventions to improve the completion proportion. 
Objectives 
The primary objective of this study is: 
1. To determine how accurately the VL suppression proportion reported in the routine ART 
programme data reflects the suppression proportion in the population on ART, given the low 
reported completion proportions. 
The secondary objective of this study is: 
12 
 
2. To identify the steps in the VL cascade that impact negatively on completion proportions and 
quantify their impact, in order to inform future interventions to improve the completion 
proportion. 
Primary objective: the suppression proportion 
Each quarter the provincial DoH reports a VL suppression proportion to the National DoH. The 
numerator is the number of patients with a VL < 400 copies/ml. The denominator is the total 
number of patients with VL results captured electronically and included in the report. If more than 
one VL is captured for a patient within an allocation window, only the VL taken closest to the due 
date is used when calculating the suppression proportion. For example, a patient with an 
unsuppressed VL at 12 months and a suppressed VL at 15 months is counted as unsuppressed. 
Quarterly reports are facility-specific, and the numerator and denominator include only ART-naïve 
patients who initiated and remain in care at the reporting facility. Patients with prior ART experience 
and patients who transferred in to their current facility after initiation elsewhere are excluded. From 
preliminary analysis it is known that this may exclude as many as 25% of patients on ART and in care. 
Patients with no VL result captured electronically are excluded from the numerator and 
denominator of the calculated proportion. This may exclude as many as 45% of patients on ART and 
in care.(12) 
It is not known whether these exclusions impact on the validity of the reported VL suppression 
proportion and, in the context of 90-90-90, how accurately the reported VL suppression proportion 
for naïve cohorts reflects progress towards suppression in 90% of the total population on ART. This 
study aims to compare the suppression proportion for naïve cohorts in Khayelitsha reported in the 
quarterly reports produced by PHCIS to the suppression proportion for all patients on ART in 
Khayelitsha calculated using all laboratory data available in the Provincial Health Data Centre 
(PHDC). 
The PHDC has been described in detail elsewhere.(13) Briefly, the various health information 
systems used in PGWC health services use a single unique patient identifier, allowing for data 
imported from these systems to the central repository to be linked to create meaningful longitudinal 
patient records using data from across these various sources, including the laboratory systems. As 
such the PHDC data provides the most comprehensive and accurate view of viral load suppression 
for the population on ART in the Khayelitsha Cohort during the study period, and constitutes the 
best available standard against which to compare the suppression proportion reported using PHCIS. 
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Secondary objective: the viral load cascade 
Routine VL results are expected for all patients on ART and in care at four months on ART, again at 
12 months and every 12 months thereafter. As indicated in the provincial treatment guidelines, 
patients may have VLs taken more frequently following a high VL, due to 2nd and 3rd line regimens, 
comorbidities, in infancy, during pregnancy and while breastfeeding, but at a minimum routine VLs 
would still be expected.(11) The required steps that must be completed for an expected VL to be 
reported as done and counted in the VL completion proportion can be broken down as follows 
(Figure 2): 
0. expected: using routine clinical data and treatment Guidelines, PHCIS can produce a list of 
patients on ART and in care with a VL expected in a specified timeframe. 
1. taken: a blood sample must be taken within the timeframe around the due date and sent to 
the laboratory. 
2. done: the VL test must be done by the laboratory and the result imported into the PHDC and 
linked to the patient. 
3. filed: the test result sheet must be delivered to the facility or printed at the facility and filed 
by a clerk in the patient folder, available for the clinician. 
4. noted: at the next visit, the clinician assessing the patient must write the result into the visit 
summary (clinical notes) that are filed in the patient folder. 
5. captured: the result must be captured electronically by a clerk into PHCIS along with other 
routine clinical data. 
It is possible for an expected VL to fail to successfully progress through any of the steps in this 
cascade. In general, failures higher up the cascade have the most negative impact on the completion 




Figure 2: Viral load cascade - from expected to captured 
The most concerning failure is at step 1: if the expected viral load is not taken then none of the 
patient or programme level benefits of routine VL monitoring highlighted above can be realised. 
However, there is no feasible way to assess step 1 directly (which would involve implementing a 
parallel monitoring system at the laboratory), so failure at step 2 will be assumed to imply failure at 
step 1, i.e. the absence of a result in the laboratory data in the PHDC will be assumed to imply a 
failure to take the blood sample within the timeframe with this limitation of indirect observation 
noted. This is justified because if a blood sample is taken but a test result is not produced (e.g. due 
to a contaminated/expired sample) then the patient should be recalled and a second sample should 
be taken. 
Failure at step 3, where the results sheet is not filed in the folder, suggests that the result was 
unavailable to the clinician at the time of clinical assessment, i.e. in the patient’s presence. This is 
almost as bad as the first failure in its impact on clinical care and perhaps worse at a programme 
level insofar as the public health system has paid for a test that is, in effect, wasted. Conversely, 
successful progress to step 3 implies that the VL was done and the result was available to the 
clinician at the next clinical assessment of the patient. So, from a clinical care perspective, this is the 
most important step in the cascade. 
There is a caveat to this last concern in some facilities where clinicians can access VL test results 
stored electronically in the laboratory database via a web browser interface when connectivity is 
available. However, this is still a problem from both a medico-legal perspective (the physical result is 
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required to be available in the folder for audits and investigations) and because it adds a further 
technological and infrastructural dependency at provincial facilities that are experiencing many 
challenges in these areas. 
Failure to progress to step 4 may only indicate a failure in clinical record keeping, which may still 
have a negative impact on a patient’s continuity of care when other clinicians attempt in the future 
to quickly assess a patient’s history using the visit summary (in large public healthcare facilities in 
South Africa, patients are unlikely to see the same clinician consistently, and so the presence of a 
consistently maintained clinical record is especially important for continuity of care). There is also an 
issue of potentially wasted resources here because, in the absence of clinically noted results, tests 
may be repeated unnecessarily. 
Finally, failure to electronically capture results compromises the accuracy of potentially useful 
patient management and programme monitoring reports produced by the electronic system, PHCIS. 
Such reports are used to identify patients due for their routine VL test, facilitate follow-up of virally 
unsuppressed patients and report on viral suppression for programme evaluation. 
This study aims to “follow” a sample of expected VLs through the cascade to identify the furthest 
step along the cascade that each VL successfully reached, and quantify the proportion of failure to 
progress at each step. 
Methods 
Study design 
This study will consist of two parts. In the first part data from two electronic sources, PHCIS and the 
PHDC, will be merged to allow for a comparison of the suppression proportion for naïve cohorts in 
Khayelitsha reported in the quarterly data using PHCIS to the suppression proportion for all patients 
on ART in Khayelitsha calculated using all laboratory data available for these patients in the PHDC. As 
discussed above, PHCIS can produce the beginning of the cascade (step 0, Figure 2) consisting of all 
routine VLs expected in the year from 1 July 2015 to 30 June 2016 for patients on ART and in care at 
provincial primary healthcare facilities in Khayelitsha. It can also indicate which patients with 
expected VLs are included in reported suppression proportions and will include some common 
patient characteristics like age, sex and duration on ART. The PHDC will provide the laboratory data 
consisting of VLs done (step 2), including the actual test result values to allow for categorising VLs 
into suppressed and unsuppressed. 
A logistic regression or log binomial model (depending on the distribution of the data) will be 
performed on this merged cross-sectional dataset to test for an association between reporting and 
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suppression, i.e. is a suppressed VL result more or less likely than an unsuppressed VL result to be 
included in the reported suppression proportion? This bears directly on the question of how 
accurately routinely reported VL suppression proportions reflect progress towards the 90-90-90 
target of 90% suppression in this population. 
In the second part of this study, the merged dataset from PHCIS and the PHDC will allow for the 
identification of all routine VLs that were done (step 2) but were not electronically captured (step 5). 
From this list, a facility-clustered random sample will be drawn for a folder audit. The folder audit 
will consist of visiting the facility, drawing the physical patient folder and examining whether the 
laboratory test result sheet was filed by the clerk in the folder and whether the result was noted by 
the clinician in the visit summary. From the folder audit, completion proportions for each step in the 
VL cascade will be estimated. 
Setting 
The Khayelitsha cohort has been described in detail elsewhere.(14) Briefly, Khayelitsha is the largest 
township in Cape Town, and the second largest township in South Africa. No published up-to-date 
population estimates exist, with the last official census from 2011 putting the estimate at just under 
400 000, and community-based organisations reporting close to 2 million by 2016.(15) The area is 
crowded and poor, with an estimated 7 748 inhabitants per square kilometre and employment rate 
of about 53% in 2011.(16) HIV prevalence is high: 34.3% of pregnant women in 2012 were HIV-
positive.(17) Government HIV services were first offered to pregnant women in Khayelitsha in 1999, 
and the ART programme was started in 2001.(14) Provincial ART services in Khayelitsha are offered 
at three large primary healthcare facilities, all of which will be included in this study. 
Population and sampling 
In the study period, there were about 22 000 patients accessing ART services at provincial primary 
healthcare facilities in Khayelitsha and therefore eligible for selection into the study. For selection 
into the study patients must be on ART and remaining in care in the study period at one of the three 
provincial ART facilities and have a routine VL expected during the study period. The guidelines for 
routine VL testing have been described above. For this study, the definitions of “on ART” and 
“remaining in care” are taken from the National guidelines: 
• Patients are on ART if they have commenced treatment on three or more antiretroviral 
drugs at any time. 
• Patients are remaining in care on a particular date if they have no manually captured or 
calculated outcome before or on that date. Outcomes that may be captured are death, 
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transfer out and confirmed loss to follow-up. The only calculated outcome is unconfirmed 
loss to follow-up, where a patient on ART has not been clinically stopped and has not had 
drugs in hand for 90 days or more.(18) 
The study period is from 1 July 2015 to 30 June 2016. PHCIS will be used to produce the list of 
patients as it has the relevant routine patient-level ART data and reporting algorithms aligned with 
the guidelines referred to above in its database. For comparing the reported completion proportions 
in the first part of this study, all required data exist in the PHDC and PHCIS databases, so all eligible 
patients will be included and sampling is not required. For the second part of the study, proportions 
at steps 2 (done) and 5 (captured) can be calculated using all patients. For steps 3 (filed) and 4 
(noted) data abstraction from folders is required, which is time consuming and necessitates 
sampling. A subset of about 1 000 such folders will be randomly sampled for physical audit, clustered 
by facility. 
Data access 
Access to patient-level ART programme data written on the patient stationery, captured 
electronically and stored in the PHCIS and PHDC databases as part of routine monitoring and 
evaluation will be requested from the DoH in the PGWC. Requests to use patient-level data for 
research purposes are handled by the Provincial Health Research Committee (PHRC) in the PGWC. 
Access to physical patient folders will be facilitated by the HIV/AIDS, STI and TB (HAST) Medical 
Officer for the Khayelitsha and Eastern Substructure (KESS) in the PGWC working with the Facility 
Managers and every effort will be made to minimise the impact on the routine operations of the 
facilities involved. Folders will be reviewed by provincial DoH staff and UCT data support staff 
seconded to the Substructure office with approved access to these data as part of delivering and 
supporting routine services. All data will be anonymised prior to analysis. 
Data management 
Patient-level data are routinely collected by provincially-employed healthcare workers into 
standardised provincially-approved paper and electronic monitoring and evaluation tools. Data 
collected using these tools are imported into the PHDC. Patient linkage (de-duplication) is performed 
as part of the import process into the PHDC. Only data linked to patients in the Khayelitsha cohort 
will be requested. Data will be stored on an encrypted drive and only the principle investigator and 
supervisors will be granted access. Folder audit data will be captured directly to an encrypted, 
password-protected Microsoft Access 2016 database and stored electronically only. No paper 
records will be generated or kept. Data will be anonymised prior to extraction from this secure 
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database for analysis by excluding identifying data from the extract process. The identifying data 
here consists only of the PGWC unique health patient identifier. 
The data elements requested will be limited to the routine ART programme data and laboratory VL 
data as detailed below. No additional data beyond the routine elements will be collected or stored. 
Limitations 
Several issues may complicate this study. The quality of routine data cannot be guaranteed. For 
example, the dates on which routine VLs are expected are calculated based on other data collected 
routinely by the ART programme, specifically baselines and outcomes. Errors in the capture of these 
data could lead to errors in the calculated due dates for routine viral loads or the incorrect 
expectation of VLs for patients no longer in care. 
Some patients may have had a VL taken elsewhere than at their routine treatment facility. In this 
case, it would be unreasonable to expect that VL to have been written in the visit summary, 
electronically captured or reported at the routine treatment facility. However, in the apparent 
absence of this VL result at the facility, the clinician should have ordered another VL, so the absence 
of a result at the routine facility is still counted as a failure. 
Despite every effort it will not be possible to locate every physical folder sampled. Folders not found 
will be assumed to be missing completely at random and treated as missing data in the analysis. 
Based on an unpublished pilot study conducted by the health services, we expect less than 10% of 
folders to be missing. 
Folders that have gone missing are usually replaced, and so it is possible that a new (“duplicate”) 
folder will have been opened for a patient between the time the VL was taken and the folder audit. 
Where folders are found with no clinical notes from the study period, these folders will be treated as 
missing, as above. 
Similarly, a results sheet may have been filed (step 3) but subsequently lost, i.e. it may have been in 
the folder at the time of the clinical assessment but it may no longer be in the folder at the time of 
the folder audit. This is unfortunately a risk that must be accepted, but previous work has shown 
many results sheets present in folders from more than 10 years earlier, and hopefully the chosen 
study period’s recentness mitigates against this risk. 
Finally, if a VL is captured electronically with the incorrect date, this may lead to it falling outside of 
the period during which it can be counted. But, where this has happened, it still reflects a failure of 




Data from PHCIS, PHDC and results from the folder review will be merged and a dataset will be 
prepared for separate analysis. The data elements are described in Table 1. The data will be explored 
using univariate and bivariate statistics. The distribution of continuous covariates will determine 
whether medians and inter-quartile ranges or means and confidence intervals are reported. 
Frequency tables will be populated for categorical and binary covariates. 
For the first objective, the overall suppression proportion using all VL done will be compared to the 
suppression proportion using only VL included in routine reports (reported). Suppression proportions 
will also be compared at various commonly used suppression thresholds, i.e. at 50, 200, 400 and 
1 000 copies/mL. This will fulfil the primary purpose of this study and give an estimate of how 
accurately reported VL suppression reflects suppression in the population on ART in Khayelitsha. 
For the second objective, the proportion of expected VL successfully reaching each step of the VL 
cascade will be estimated. A logistic regression will be performed to determine factors associated 
with two important steps along the cascade: a) VL test done (step 1) and b) VL test completed the VL 
cascade to be included in routine reports (reported), representing “actual completion” and 
“reported completion” respectively. 
Note that in the encrypted database the folder number is required in order to complete the folder 
audit, but it is not required – and will be removed prior to export – for the subsequent analysis. All 
analysis will be performed in STATA 14 (StataCorp. 2015. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP). 
Table 1: Data elements 
Variable Type Comment 
patientid integer unique, anonymous patient identifier for study 
facility integer unique, anonymous facility identifier 
age number age at VL due date 
sex integer sex (0=male, 1=female, 2=other) 
pregnant integer pregnancy status at VL due date (1=pregnant) 
timeslot integer duration on ART at VL due date 
opendate date start of VL allocation window 
closedate date end of VL allocation window 
duedate date due date for expected VL 
labval integer lab test result value (“LDL”=0) from PHDC 
labdate date lab test date from PHDC 
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capval integer captured test result value (“LDL”=0) from PHCIS 
capdate date captured test date from PHCIS 
done binary lab/captured date within VL allocation window 
*filed binary VL result sheet filed 
*noted binary VL result noted in visit summary 
captured binary result captured to the electronic system 
reported binary result reported in the naïve cohort quarterly reports 
suppressed50 binary result < 50 copies/ml 
suppressed200 binary result < 200 copies/ml 
suppressed400 binary result < 400 copies/ml 
suppressed1000 binary result < 1000 copies/ml 
*reviewed Binary physical folder manually reviewed (1=yes) 
*reviewer text name of person who reviewed folder 
*reviewdate date date on which folder was reviewed 
* These elements will be captured by the reviewer during the physical folder audit 
Ethics 
Ethical review 
Ongoing collection of routine data is performed by the DoH in the PGWC. Research use of this 
routine data for the Khayelitsha Cohort has already been approved by the University of Cape Town 
Human Research Ethics Committee (HREC REF Number 395/2005, updated annually). No additional 
data elements will be collected. The review of folders for missing viral load results not captured 
electronically constitutes a data cleaning exercise as these results should have been captured as part 
of routine DoH data collection to PHCIS anyway. Missing results found during folder review will be 
imported into PHCIS. Only staff with existing approved access to these data will work on this study; 
no new data access will be granted. 
Risks and benefits 
This research will make use of existing data collected as part of routine monitoring and evaluation, 
including data collected electronically and manually to the patient folder. No folders or other 
documentation will be removed from the facility. Data abstracted from folders will be captured 
directly to an encrypted database. The primary risk of this study is to patient privacy and 
confidentiality, and every effort to mitigate this risk will be taken. Other than concerns around 
privacy and confidentiality addressed explicitly below there is no risk to the health or wellbeing of 
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patients as there will be no contact with patients and no changes to the care already received. As 
such, we are requesting a waiver of the requirement for informed consent. 
There is no direct benefit to patients anticipated, but this research seeks to inform the interpretation 
of routinely reported data, and inform future interventions to improve the handling and capture of 
VL test results, to make it more likely that a VL test is performed, that the result is available to the 
clinician at the time of assessment and that the result is used in routine reporting. As such it is hoped 
that this research may have an indirect benefit to patients by improving the understanding of the 
ART programme and by guiding interventions to improve the health system. As such it is intended to 
provide improved insight for programme managers and direction to those working on health 
systems strengthening. 
Privacy and confidentiality 
The review of physical folders would not be possible without the availability of the folder number to 
link the data from the electronic systems to the offline data in the physical folder at the facility. This 
folder number is an integer, eight or nine digits long, that contains no personally identifiable 
information, and no other personally identifiable information will be captured or stored in this study. 
However, those with approved access to provincial electronic health information systems, and 
access to physical folders in facilities, could identify the patient using this number, hence it is not 
truly anonymous. 
As stated above, the folder reviewers involved in this study are employed by or seconded to the DoH 
in the PGWC and already have access to this data, so no new access will be granted for the purposes 
of this study. Datasets containing the folder number will only be stored electronically and always 
encrypted and password protected. Following the folder review, the data will be truly anonymised 
by removal of the folder number prior to export for analysis. Furthermore, this study will be 
conducted with direct oversight from the substructure Medical Officer who will monitor study 
activities closely. As such, the risk to patient privacy and confidentiality is perceived to be minimal. 
Timeframe 
The timeframes for this research are heavily dependent on approval from the University of Cape 
Town (UCT) Faculty of Health Sciences Human Research Ethics Committee (HREC) and data access 
from the DoH in the PGWC. However, the intention is to submit the manuscript in the fourth quarter 
of 2017. The proposed timeline is detailed below (Table 2): 
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Table 2: Proposed timeline 
Month JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC 
Literature review             
Stakeholder 
engagement 
            
Data collection             
Data cleaning             
Data 
management 
            
Data analysis             
Results             
Write-up             
Dissemination of research findings 
A summary of research findings will be presented to Facility Managers, the Director of the 
Khayelitsha and Eastern Substructure and their staff, the Director of HAST in PGWC, and 
investigators will avail themselves to respond to any questions about the research and findings. 
The Centre for Infectious Disease Epidemiology and Research (CIDER) at the University of Cape Town 
will be approached with an offer to present a summary of the research findings at the regular 
Academic Lunch events held within the Centre. A journal-ready manuscript will be produced in 
partial fulfilment of the requirements for the degree of Master of Public Health (Epidemiology and 
Biostatistics). This manuscript will be further worked on before being submitted to journals, 
hopefully resulting in a journal publication. 
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Part B: Literature Review 
Introduction 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the 90-90-90 strategy in 2013 
with the goal to end the AIDS epidemic by 2030.(1) HIV treatment can be viewed as a cascade from 
diagnosis to viral suppression. The 90-90-90 strategy identified targets to reach by 2020 at three 
steps along this cascade: 
1. 90% of people living with HIV (PLWH) will know their status; 
2. 90% of people diagnosed with HIV will receive sustained antiretroviral therapy (ART); and 
3. 90% of people receiving ART will have viral suppression. 
Due to the cascading nature of the target proportions, the second and third 90s can also be stated as 
“81% of PLWH will receive sustained ART” and “73% of PLWH will be virally suppressed” 
respectively. 
The targets are self-consciously ambitious and simplified, intended to “drive progress…, promote 
accountability and unite diverse stakeholders in a common effort.”(1) The strategy has been widely 
adopted, with many publications reporting on progress towards the targets in different populations 
and settings. However, there is a diversity of interpretation of these targets and there is also 
diversity in the approaches to measure progress against the targets and the types of data sources 
used. 
This literature review focuses on the third 90: viral suppression in the population on ART in the 
context of the 90-90-90 strategy. It aims to describe and synthesise the currently published 
literature on progress towards the third 90 and identify where further research is needed. 
Objectives 
The aim of this literature review is to systematically synthesise English-language literature published 
before 1 December 2017 reporting on viral suppression in the context of the UNAIDS 90-90-90 
strategy. The review will describe the study designs, populations, definitions, data sources and 
analytical methods used. It will highlight similarities and differences between approaches, and draw 
attention to ambiguities and missing information and the limitations these place on appropriate 
comparison and interpretation of reported results. The focus here is methodological; the reported 
suppression proportions are summarised in Table 1 but will not be discussed. Note that technical 
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details about storage times and temperatures and assay methods for laboratory measurement of 
viral load and discussion thereof are beyond the scope of this review. 
There is more than one legitimate approach to measure progress against the third 90 in the 90-90-
90 targets. Different settings provide different opportunities for analysis. In some settings, rich 
routine datasets are available, but access to viral load testing in most resource-limited settings has 
been scarce and routine viral load monitoring has not been implemented until recently. In some of 
these contexts, population-based surveys have produced broadly representative datasets while 
elsewhere it has been necessary to produce modelled estimates based on minimal data. Following 
similar approaches in different settings can lead to better comparability, but can also have the effect 
of introducing a “lowest common denominator” effect in which more valid measurements based on 
richer datasets are ignored in favour of estimates derived using a common approach. 
Search strategy 
PubMed was searched using the terms 90-90-90[Title/Abstract] AND (HIV[Title/Abstract] OR 
ART[Title/Abstract] OR antiretroviral[Title/Abstract]) to identify publications reporting on progress 
towards the 90-90-90 targets. The search returned 167 publications, which were examined to 
determine if they reported against the third 90: viral suppression in the population on ART. No 
exclusion criteria were applied on the basis of geography, study population or year of publication. 
However, the 90-90-90 strategy was only proposed by UNAIDS in 2013 and this search was 
performed in December 2017, with the result that all studies included were published between 
these dates. 
The inclusion of 90-90-90 in the search terms had a significant effect on the number of results 
returned; removing this term returned 347 837 results. This significant restriction was helpful as it 
focused the review on publications reporting on progress towards the 90-90-90 targets, which is the 
focus of this research. Furthermore, the 90-90-90 targets have been so widely adopted that few 
authors reporting on the HIV treatment cascade at a population level (including key populations) fail 
to place their research in the context of the 90-90-90 targets since their inception. 
Reference lists of included publications were also reviewed. Results from the Population-based HIV 
impact assessments (PHIAs) were not included as results are preliminary and not yet published in a 




Summary and interpretation 
The search yielded 167 publications, 25 of which reported on viral suppression. One publication was 
added from references. Table 1 summarises the study design, geographical context, study 
population and ART experience inclusion criteria for each of the reviewed studies. These features are 
discussed in more detail below. 
Study design 
All studies reviewed used either a cohort (including cohorts from trials) or cross-sectional design 
(Table 1). In practice, the study design and data sources largely determine the study population: a 
retrospective cohort study using routine data collected at a single facility can only include HIV 
patients currently or previously in care at that facility, while a population-based survey can include 
both those who have linked to care and those who have not but, due to non-responses, may miss 
some of the patients in care that the cohort study would have included. 
Many of the studies reviewed also reported on progress against the first 90 (testing) and second 90 
(linkage to care). Population-based surveys are the most commonly used method to assess progress 
against the first and second 90s because they seek to include those in the community who have not 
tested or who have tested and not linked to care. When assessing the third 90 – viral suppression 
among people receiving ART – the denominator as defined by UNAIDS includes only those who are 
in care. 
There is room for confusion in the classification of these studies as either cohort or cross-sectional. 
In some cases the confusion is due to a combination of data collected using different methods. For 
example, survey data and longitudinal patient-level programme data were combined by Billioux et 
al. to allow for estimates of progress towards all three 90-90-90 targets.(2) For the purposes of 
classification in Table 1, the study design is indicated as specified by the authors unless it clearly did 
not apply to the method used to measure progress against the third 90 specifically. 
While the surveys fit neatly into the cross-sectional classification, a retrospective cohort study using 
the latest viral load for all patients in care at a particular timepoint may in fact be more like a cross-
sectional study. For example, Ndahimana et al. conducted a nationwide retrospective cohort study 
in Rwanda in which data were collected for a sample of patients still on ART at their initiation facility 
at 11-13 months who were invited to provide a blood sample for viral load testing and resistance 
genotyping.(3) In practice this amounts to a cross-sectional estimate of viral suppression among 
patients in care at the facility at a particular timepoint. 
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Table 1: Summary table of reviewed studies 
















Billioux, 2017(2) Cohort 2015 Uganda (Rakai) 15-49 Naïve 12 1000 92 
Boullé, 2016(4) Cross-sectional 2014 Cameroon (Mfou) ≥15 Naïve ≥6 1000 76 
Bowman, 2017(5) Cohort 2015 Dominican Republic “adult” Naïve 12 20 57 
Chkhartishvili, 2016(6) Cohort 2015 Georgia All? All?  1000 85 
Chkhartishvili, 2017(7) Cohort 2014 Georgia ≥18 Naïve  1000 89 
Drew, 2017(8) Mixed 2014 Europe, Central Asia All All  Mixed 73 
Gaolathe, 2016(9) Cross-sectional 2015 Botswana 16-64, citizens All  400 97 
Gisslén, 2017(10) Cross-sectional 2015 Sweden All All ≥6 50, 200 95, 99 
Gourlay, 2017(11) Cohort 2013 Europe, Central Asia ≥15 All  200 85 
Grobler, 2017(12) Cross-sectional 2015 South Africa (KZN) 15-49 All  1000 88 
Iwamoto, 2017(13) Cross-sectional 2015 Japan All All ≥6 20, 400 94,99 
Jiamsakul, 2017(14) Cohort 2017 Global <18 
≥18 
Naïve 12, 24, 36 1000 80 (child) 
90 (adult) 
Johnson, 2017(15) Modelling 2015 South Africa All All 48 400 78 
Kerrigan, 2017(16) Cohort 2016 Tanzania (Iringa) ≥18, FSW Naïve  400 70 
Kim, 2016(17) Cross-sectional 2013 Kenya (Ndhiwa) 18-64 All  1000 79 
Kwarisiima, 2017(18) Cohort 2015 Uganda, Kenya CD4 ≥350 Naïve 12 500 93 
Labhardt, 2017(19) Cohort 2014 Lesotho ≥16, VL ≥80 Naïve ≥24 80 91 
Maman, 2016(20) Cross-sectional 2013 Malawi 15-59 All  1000 90 
Maman, 2015(21)s Cross-sectional 2012 Kenya 15-59 All  1000 84 
Maskew, 2016(22) Cohort 2015 South Africa 12-20 Naïve  400 69 
Naidoo, 2017(23) Cohort 2017 South Africa (KZN) ≥14 Naïve 12, 24, 36, 
48, 60, 72 
400 90 (male) 
96 (female) 
Ndahimana, 2016(24) Cohort 2011 Rwanda ≥15 Naïve 12 400, 1000 86, 88 
Raymond, 2016(25) Cross-sectional 2014 USA (SF) ≥18, MSM All  200 89 
Takuva, 2017(26) Cohort 2012 South Africa All All  400 74 
Xia, 2016(27) Cross-sectional 2014 USA (NYC) All All  200 86 
Zhang, 2016(28) Cross-sectional 2014 China (Shandong) ≥18 months All  50 60 
Key: KZN=KwaZulu Natal; SF=San Francisco; NYC=New York City; FSW=Female Sex Workers; MSM=Men who have Sex with Men; Duration on ART blank if not explicitly 
selected/stated; VL=Viral Load 
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It complicates matters still further when the viral load test result is also used as the signal for being 
in care.(26) Takuva et al. assessed progress against the third 90 using only laboratory data and 
therefore relied on laboratory results alone to determine both the numerator and denominator of 
the viral suppression proportion. The issue with this approach is that the gaps in the data cannot be 
seen: patients in care without virological outcomes cannot be identified and patterns in their 
characteristics cannot be assessed. This is concerning because guidelines recommend viral load 
testing at different frequencies for different groups of patients, so it should be expected that certain 
groups will be over-represented such as patients who are sick or where there are concerns about 
non-adherence. Jiamsakul et al. excluded patients with no viral load tests results available after 
initiation, which would raise similar concerns but to a lesser extent as they did not rely entirely on 
the presence of viral load test results.(14) 
Population 
Geography 
The study populations of the studies reviewed ranged in geographical coverage from a single 
facility(29) through the city(25,27), provincial(12,23) and national(15) levels, up to the global 
level.(14) As discussed above, the choices of study design and availability of data largely determine 
the study population. Similarly, though, the choice of study population may inform the choice of 
study design and data sources, depending on data availability for that population. 
In many cases different facilities within the same district collect different data in different ways, let 
alone across countries. Only two of the reviewed studies reported suppression across multiple 
countries. Gourlay et al. reported on countries in Europe and Central Asia, whereas Jiamsakul et al. 
reported on countries in the International Epidemiologic Databases to Evaluate AIDS (IeDEA) 
Collaboration including 16 countries in North America, the Caribbean, Central and South America, 
Asia-Pacific and Africa.(11,14) Both studies faced significant challenges with data availability, 
standardisation and comparability, as discussed under the relevant headings below. For example, 
due to the relatively recent introduction of routine viral load monitoring in most of sub-Saharan 
Africa, the only country in the region with enough data to be included by Jiamsakul et al. was South 
Africa.(14) 
Age 
Age categories were inconsistently defined across studies and no reasons were given for the chosen 




• An adult is a person older than 19 years of age. 
• An adolescent is a person 10–19 years of age inclusive. 
• A child is a person 1 to younger than 10 years of age. 
• An infant is a child younger than 1 year of age. 
These age categories are useful because they facilitate focus on infants, children and adolescents, 
vulnerable sub-populations that may face quite different challenges. However, these cut-offs do not 
align with those used more broadly across health programmes in different countries, and even 
studies focused on these sub-populations are not consistent. The single paediatric-focused study 
reviewed included all participants aged <16 years, and the single adolescent-focused study reviewed 
included participants aged 12-20 years.(22) 
Most studies reviewed used 15 years as the binary cut-off between children (<15) and adults (≥15), 
and most of these included only adults (≥15), but ages 12, 16 and 18 years were also used as cut-offs 
(see Table 1). At the other end of the spectrum, studies used various upper bounds of between 49 
and 64 years with no reasons given. It cannot be assumed that viral suppression in those older than 
these thresholds is the same as in those younger, and the utility of explicitly excluding older patients 
is not obvious. In fact, there is a growing body of evidence that ageing cohorts play an important role 
in the HIV epidemic.(31) 
Key populations 
Studies reporting exclusively on progress towards the third 90 in children, adolescents, men who 
have sex with men (MSM) and female sex workers (FSW), and studies that included (and highlighted) 
results for these groups within the broader population, were included in the review (see Table 1). 
Comparing progress against the 90-90-90 targets across key populations and the broader population 
provides a useful way to identify barriers to care or where current models of care may be failing 
some sub-populations. No studies reported on progress towards the third 90 in people in prisons, 
people who inject drugs and transgendered people were reviewed, and this may indicate gaps in the 
current literature. 
Inconsistency in the categorisation of age-based vulnerable populations has been addressed above. 
ART experience 
Most of the cohort studies reviewed – including retrospective cohorts derived from existing routine 
data – included only ART-naïve patients initiating at the study sites of interest, explicitly excluding 
patients with prior treatment experience. Population-based surveys by their very nature include not 
only those with prior treatment experience but also those with no treatment experience, i.e. those 
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that have no past or current link to HIV care, but almost all relied on self-report to determine 
whether or not participants were on ART. 
Definitions and measurements 
Definition of suppression: the numerator 
In the seminal 90-90-90 document from UNAIDS, there is only one mention of a viral load 
suppression threshold: the y-axis in Figure 16, which reports on the “Proportion Of People On Art 
With Viral Suppression In Latin America And The Caribbean, 2013”, is labelled “Percent suppressed 
viral load (<1,000 copies)”.(1) 
The use of different absolute value thresholds for viral suppression makes comparison across studies 
and settings difficult. In the publications reviewed, thresholds ranged from 20 copies/ml to 1 000 
copies/ml (Table 1). Reporting suppression at more than one threshold is helpful to enable 
comparability between studies. However, in the studies reviewed only two reported at more than 
one threshold, and coincidentally there was no threshold in common between the two, thus direct 
comparison was still not possible. (3,10) 
What makes comparison even more difficult is failure to report thresholds along with suppression 
proportions. In a study using a country-based questionnaire, Drew et al. reported, “Of the 25 
countries reporting data, 44% reported the threshold they used.” (8) If the suppression threshold is 
known to be different and the difference is known then it can perhaps be accounted for. If it is 
unknown, it is not possible to make any reasonable comparison. 
As defined by UNAIDS, the second 90 says people “will receive sustained ART” but the third 90 says 
only “will have viral suppression”.(1) Some authors like Gisslén et al. define the third 90 as “should 
have durable viraological (sic) suppression”, yet report suppression based on most recent VL.(10) 
They have even reported this as a limitation: “Using a single VL measurement may also overestimate 
durable viral suppression”, but this is not strictly a limitation on validity as per the UNAIDS target. 
Chkhartishvili et al. reported separately on viral suppression using each of two interpretations of 
viral suppression: “Ever Suppressed” and “Maintained Suppression”.(7) Of 1 044 patients who were 
virally suppressed during the study period (Ever Suppressed), only 792 (88%) were virally suppressed 
throughout the study period (Maintained Suppression). The authors also reported that 902 (89%) of 
1011 patients on ART at the end of the study period were virally suppressed, which is how most of 
the reviewed studies (cohort and cross-sectional) interpreted the third 90. 
This raises a concern: preventing transmission is an important corollary of suppression and one of 
the main goals of the 90-90-90 strategy, but can be realised only with sustained viral suppression. As 
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it is currently defined by UNAIDS, the third 90 target does not require viral suppression to be 
sustained, and reporting on sustained viral suppression may be too onerous in many settings. 
Nonetheless, Chkhartishvili et al. are right to draw our attention to this as another important 
consideration towards preventing transmission and thereby realising the main goal of 90-90-90: 
ending the AIDS epidemic. 
Definition of suppression: the denominator 
All survey studies reviewed relied on self-report to determine current ART status and estimate the 
number of participants receiving ART, used as the numerator of the second 90 and the denominator 
of the third 90. Self-report may lead to overestimation of the second 90, and underestimation of the 
suppression proportion in the third 90 (due to overestimation of the denominator). In an effort to 
limit overestimation, one survey required participants to produce some evidence of receiving 
ART.(9) Another study was more concerned with underestimation of ART coverage, accepting either 
self-report or record of an ART start date in routine data.(2) 
Estimation of the denominator is also complicated by confusion about what constitutes “sustained 
antiretroviral therapy”. While active transfer out and mortality are relatively well defined (even if 
not well ascertained), different studies have used very different definitions of “remaining in care” 
(RIC) and “loss to follow-up” (LTF). For example, in the absence of a recorded outcome, Jiamsakul et 
al. defined a patient as LTF if no visit was recorded within six months of the closing date, compared 
to Zang et al.’s RIC criterion of “≥2 CD4 count or VL test results separated by ≥90 days”.(14,28) 
In South Africa, the National Guidelines define LTF as 90 days with no medication in hand.(32) At 
each visit, ART patients are given a next appointment date and enough medication to last until 
shortly after that appointment date, so a patient would usually be classified as LTF at roughly 90 
days after a missed appointment. However, there is not inherently any longitudinal nature to this 
definition. At any chosen timepoint, patients are classified as RIC if they fulfil the relevant criterion at 
that timepoint, not if they have consistently fulfilled that criterion for a period of time prior to that 
timepoint. Thus a patient who returns to care just before the time point after significant 
interruptions in care will be counted as RIC. 
Counting these patients in this way has the effect of shifting the burden from the second to the third 
90, because they are counted in the numerator of the second 90 and the denominator of the third 
90. In other words, it may be unreasonable to expect these patients to have achieved viral 
suppression (the third 90) because they have not received sustained ART (the second 90), and 




Indeed, it might be argued that there are two distinct 90s hidden in the second 90 – linkage to care 
and retention in care. Population-based surveys tend to provide a more thorough approach to 
measuring the first 90 (testing) and the first part of the second 90 (linkage to care), while the use of 
routine clinical records in retrospective cohort studies tends to provide a more thorough approach 
to measuring the second part of the second 90 (retention) and the third 90 (suppression among 
those retained in care). 
Data sources 
Data sources used in the studies reviewed ranged from computer-assisted personal interviews 
(combined with study-specific laboratory test results) for population-based surveys to 
questionnaires for country-based surveys, from small study laboratories to national laboratory data 
warehouses, and from surveillance systems to patient-specific electronic medical records. As 
discussed above, choices of study population, design and data sources are closely interlinked and 
interdependent. In some settings, rich routine data sources are available for use but, even then, 
population-based surveys may extend the reach of the study to populations not otherwise included. 
In other settings where there is a paucity of data, such surveys may be the only immediately feasible 
method to assess progress towards to the 90-90-90 targets. 
Completeness 
As discussed above, the numerator of the third 90 is the number of those with a viral load less than a 
threshold and the denominator is those receiving sustained ART (i.e. the numerator in the second 
90). Alternatively, the third step in the cascade can be defined as 73% of PLWH (i.e. the numerator 
of the first 90). However, viral load results are not usually available for each and every one of those 
included in either of these denominators, and it can be surprisingly difficult to ascertain the 
completeness of data used to report against the third 90. 
It is easiest to report on completeness (and mitigate incompleteness) in studies that perform study-
specific HIV and viral load tests. For example, Gaolathe et al. performed HIV testing on all 
participants without a documented HIV-positive status, and performed viral load testing on all HIV-
positive participants (known positive and newly tested). Of 2617 participants on ART, the study was 
able to include viral load results for 2609 (99.7%).(33) As such, any concerns about missing data in 
this study are more likely to stem from sampling methods or non-participation in the study rather 
than missing viral load results for participants. 
However, performing study-specific viral load tests does not necessarily overcome challenges with 
completeness. In their cohort study, Ndahimana et al. found 837 patients who met their study 
inclusion criteria, but nine patients were excluded due to missing patient folders.(3) Of the 828 
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remaining, 711 were still active at the time of data collection and invited for blood collection, of 
whom only 597 (84% of active patients) presented on data collection day.  
Working with routine data in the absence of study-specific viral load tests can present greater 
challenges with completeness. Johnson et al., looking at viral load test results at 48 months on ART 
and working with national routine data from the District Health Information System in South Africa, 
reported 55% completeness, which varied from 68% in one province to 85% in another.(15)  
In comparison, others working with routine data reported high completion. Naidoo et al. reported 
on 3547 (88%) of 4043 patients with viral load results available and Maskew et al. reported on 103 
(82%) of 126 participants with viral load results available.(22,23) 
Whether completion is high or low, it is helpful when authors report on it explicitly, as the authors 
did in each of the three studies just discussed. By contrast, Bowman et al. reported that of 88 
patients RIC at 12 months on ART, 51 (58%) had achieved viral suppression.(5) It is not clear whether 
viral load results were available for all 88 patients or missing results were counted as unsuppressed. 
Identification of gaps in research 
In order to report consistently and comparably on progress towards the target of 90% viral 
suppression in the population on ART in the context of 90-90-90, a proportion is not enough. The 
population reported on as well as the methods, definitions, thresholds, data sources used and 
completion must be explicitly reported. Where possible, multiple definitions and thresholds should 
be reported against to facilitate more direct comparisons. Different methods may be more 
appropriate in different settings and for reporting on different targets within the cascade. It would 
also be helpful to have some evidence base that would allow for correction when comparing results 
reported using different methods, and for designing interventions to improve completion in routine 
settings. 
Another facet to reporting on the third 90 target that has not been discussed is feasibility. While a 
once-off measure is useful, regularly reported measurements are required to track progress against 
the third 90. Designing and deploying regular population-based surveys is unlikely to be feasible and 
may be an unnecessary expenditure of limited resources in settings where adequate routine data 
are available. Furthermore, while surveys can provide helpful guidance to programmes, e.g. by 
identifying sub-populations that experience barriers to accessing care, they generally do not 




Published literature reporting on progress towards the third 90 reveals a number of different 
approaches to measuring viral load suppression in the population on ART. Different study designs, 
study populations, definitions, data sources and levels of completion may impact on the validity and 
comparability of results. 
In South Africa, each level of healthcare from facility through district and up to province reports to 
the national government on progress towards the third 90 using routine clinical data that is digitised 
on-site at facilities and then reported to higher levels in the Department of Health. Data are 
reported quarterly in the form of facility-based naïve cohort datasets. Viral load suppression is 
reported as the number of viral loads <400 copies/ml out of the number of viral loads done. Viral 
load completion is reported separately, and is often very low. 
It is not known whether low reported viral load completion is due to low adherence to virological 
testing guidelines or missing data on viral load tests done, and in the latter case it is not known what 
the cause of missing data or its impact on the validity of reported viral load suppression proportions 
might be. The effect of using a viral load threshold of 400 copies/ml rather than 1 000 copies/ml is 
not known, nor is the effect of reporting on only naïve facility-based cohorts, excluding experienced 
and transferred-in patients. 
This study aims to answer these questions by examining viral load suppression and completion in a 
high-prevalence routine care setting in South Africa. 
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PART C: Journal-ready Manuscript 
Title 
How accurately do routinely reported HIV viral load suppression proportions reflect progress 
towards the 90-90-90 target in the population on ART in Khayelitsha, South Africa? 
Abstract 
Background: The third 90-90-90 target requires 90% of patients on antiretroviral therapy 
(ART) to be virally suppressed <1000 copies/mL. Khayelitsha reported viral load (VL) 
suppression <400 copies/mL as 89% in 2016, but only 56% of patients had a result recorded 
in routine data. We conceived a “VL cascade” to represent the steps required for an expected 
VL to be reported as complete in routine data and thus contribute to reported VL suppression: 
among those for whom a VL is “expected”, a sample must be collected and tested (“done”), a 
result must be “filed” in the patient folder, “noted” by a clinician and electronically 
“captured”. The low reported completion suggested gaps along the VL cascade and cast 
doubt on the validity of reported suppression. 
Objectives: To assess the validity of routinely reported VL suppression and identify barriers 
to VL completion. 
Methods: A retrospective cohort study including all patients on ART in Khayelitsha with a 
routine VL expected between 1 July 2015 and 30 June 2016 was conducted. We obtained 
data routinely captured on-site and VL data from the laboratory system. A sample of 1 035 
physical patient folders were also reviewed. VL suppression was calculated using laboratory 
data including all tests done and compared to reported suppression based on on-site electronic 
data capture. Successful progression through each step on the VL cascade was estimated. We 
used logistic regression to identify factors associated with laboratory and reported VL testing. 
Results: Of 22 991 patients with a routine VL due, 84% were done, 79% filed, 76% noted, 
and 55% captured. Using all laboratory data, VL suppression was estimated to be 82%, 87%, 
89% and 91% at the 50, 200, 400 and 1 000 copies/mL thresholds respectively, but reported 
suppression using captured results was 80%, 86%, 88% and 89% at those thresholds. Routine 
VL were more likely to be done among children <15 years old (aOR 1.89, 95%CI 1.45–2.48) 
and pregnant women (aOR 1.90, 95%CI 1.28–2.81) compared to men, adjusted for facility. 
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Conclusion: Despite low reported completion, VL testing completion was high. Reported 
suppression using captured data was similar to suppression calculated using all laboratory 
data, providing an accurate measure of progress towards the 90-90-90 target. More work is 
needed to reach the 16% of patients missed by routine testing. 
Introduction 
The 90-90-90 strategy ambitiously aspires to have 90% of all people living with HIV 
(PLWH) know their status, 90% of those to receive sustained antiretroviral treatment (ART), 
and 90% of those to achieve viral load (VL) suppression by 2020.(1) Many studies have 
assessed progress against these targets in different settings, with significant heterogeneity in 
data sources, outcome definitions, methods and results.(2) 
The Khayelitsha Cohort in Cape Town is one of the oldest and largest HIV cohorts in South 
Africa. Free public-sector ART was initially rolled out here in 2001 in partnership with 
Médecins Sans Frontières.(3) VL testing is the gold standard in HIV treatment 
monitoring.(4,5) Unusually for a low-resource setting, VL monitoring has been widely used 
in Khayelitsha since programme inception in 2001. With approximately 22 000 patients on 
ART and in care at Provincial facilities in 2016, Khayelitsha reported almost 89% 
suppression on quarterly reports, but also reported only 56% completion of routine VL tests 
indicated by national guidelines.(6) This low reported completion does not necessarily imply 
low actual completion, as it may be the result of incompleteness in routine data capture. 
For this study, the concept of a “VL cascade” was introduced to represent the steps required 
for an expected VL to be reported as complete in routine data and thus contribute to reported 
VL suppression on routine quarterly reports (Figure 1). At the first step, among patients from 
whom a routine VL is expected, a blood sample must be taken (step 1). The VL blood sample 
must then be processed by the laboratory (step 2), the test result printed, couriered to the 
facility, sorted and distributed to the appropriate registry and filed by a clerk in the patient 
folder (step 3), the result noted by a clinician in the visit summary paper stationery at the next 
clinical assessment (step 4) and electronically captured by a clerk into the Primary Healthcare 
Information System (PHCIS) (step 5). Finally, routine quarterly ART data report on facility-
based ART-naïve cohorts, so VL results for patients who initiated outside of the facility at 
which they are now in care will not be included in reports (step 6). 
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The low reported completion for Khayelitsha in 2016 therefore raised two important 
questions: was the high reported suppression proportion a valid measure of progress towards 
the third 90, and what were the barriers to VL testing and recording of VL results in the 
context of widely available laboratory testing? This study aimed to answer these questions by 
describing a VL cascade from ‘expected’ to ‘reported’ and estimating success and failure at 
each step on the cascade. 
 
Figure 1: Viral load cascade - from expected to reported 
Methods 
Setting 
The Khayelitsha Cohort has been described in detail elsewhere.(7) Briefly, Khayelitsha is the 
largest township in Cape Town, South Africa, with a high burden of HIV. The provincial 
government has provided free ART services at primary healthcare facilities starting in 
2001.(3) Eligibility criteria have evolved in response to World Health Organisation (WHO) 
recommendations, with Universal Test and Treat adopted nationally in September 2016.(8) 
Study design 
A retrospective cohort was constructed including all patients on ART and in care at 
provincial healthcare facilities in Khayelitsha with a routine VL expected in the year from 1 
July 2015 to 30 June 2016. Ethics approval for this study was granted by the University of 




In the South African ART programme, routine quarterly reports follow naïve cohorts while in 
care at their initiating facility. Patients who die, transfer out or are lost to follow-up (defined 
as 90 days without medication in hand) exit the cohort. Even if they return to care elsewhere 
they are no longer included in the reported suppression proportion. By contrast, the intended 
denominator for the “third 90” includes all patients receiving ART regardless of where they 
access care. This study included all patients receiving ART in Khayelitsha in the study period 
irrespective of where they initiated ART but distinguishes between patients who are part of 
the reporting cohort (the naïve cohort at the reporting facility) and those who are not.  
Outcomes 
Suppression 
National guidelines define VL suppression as <400 copies/mL. While the UNAIDS 90-90-90 
document does not explicitly define a threshold, it is generally taken to be 1 000 copies/mL, 
although various thresholds have been used in different settings.(9) To assess the effect of 
using different thresholds and facilitate comparability across studies, multiple thresholds are 
reported against here. 
Completion 
Provincial guidelines recommend routine VL testing for all patients at four months on ART, 
again at 12 months and annually thereafter.(10) More frequent testing is recommended after 
an unsuppressed VL or regimen switch, in HIV-exposed infants, HIV positive children <5 
years of age and pregnant and breastfeeding women. To calculate routine VL completion, we 
calculated patient-specific time windows around each expected VL due date based on the 
patient’s ART initiation date, using the same algorithms as routine reports (Figure 2). This 
algorithm is the same for all patients despite the different clinical guidelines alluded to above. 
According to this algorithm, where more than one VL was taken within an allocation 





Figure 2: Viral load allocation – using a 24-month due date as an example 
Data collection 
We used 3 data sources to assess completion at each step in the cascade: PHCIS, the 
Provincial Health Data Centre (PHDC) and the physical patient folder containing all paper 
records at the facility (Figure 1). To assess completion at steps 0, 2 and 5 on the cascade, data 
were requested from PHCIS and PHDC. PHCIS contains routine data digitised by clerks on 
site at the healthcare facility. The PHDC contains all data from the National Health 
Laboratory Services (NHLS), which performs all VL testing for patients in care at Provincial 
facilities in Khayelitsha. All VL testing during the study period was performed by the NHLS 
using a Roche COBAS Ampliprep/TaqMan HIV-1 test v2. Step 1 could not be directly 
assessed: for example, if a test was not registered by the laboratory system due to incorrect or 
illegible request forms, it would not be counted as “done” at step 2, despite a blood sample 
having been taken within the timeframe and sent to the laboratory. Completion at steps 3 and 
4 was assessed by physical folder review, for which folders were drawn on-site at facilities 
and some data captured directly to a standalone encrypted electronic database. Routine 
patient data in all sources (physical folder, PHCIS, NHLS and PHDC) are captured and 
linked using the unique patient identifier used across the public health platform in the 
Western Cape Province.(11) 
Data analysis 
The VL cascade is simplified insofar as it reports the furthest step a VL reached on the 
cascade and assumes that the VL successfully reached all previous steps on the cascade. Only 
VLs done (step 2) but not captured (step 5) were sampled for physical folder review. The 
folder review then generated proportions of the sample that were filed (step 3) and noted 
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(step 4). These proportions (of the sample) could then be added to the proportion captured (of 
the total) to generate the proportions filed and noted on the cascade. 
Statistical analyses were performed using Stata 14 (StataCorp. 2015, College Station, TX). 
The sample of folders selected for review was prepared using the Simple Random Sample 
function in Stata, clustered on healthcare facility. 
A logistic regression model was built to investigate the effect of facility, age category and 
pregnancy status on VL testing completion (“done”) and inclusion in routine reports 
(“reported”). Healthcare facility was included to account for different operational practices at 
different facilities. Age category and pregnancy status were included because different 
models of care are provided for children and pregnant women and different clinical guidelines 
are followed. Adjusted odds ratios (aOR) with 95% confidence intervals (95%CI) were 
estimated using this model. 
Results 
There were 22 991 patients on ART and in care at provincial healthcare facilities in 
Khayelitsha with a VL expected between 1 July 2015 and 30 June 2016, of whom 18 450 
(84%) had a VL done within their window. Of these, 11 100 (60%) were included in the 
reported suppression proportion in routine data: 1 790 (10%) were excluded because the 
patients were not part of the naïve cohort at the reporting facility, and 5 560 (30%) were 
excluded because they were not captured (step 5). Of those not captured, a total of 1 035 
physical folders were reviewed, and completion at steps on the cascade was estimated to be 
84% done (VL sample taken and tested), 79% filed, 76% noted by clinician, and 55% 
captured electronically. 
Actual completion (“done”) and reported completion (“reported”) varied by facility, age 
category and pregnancy status (Table 1). Expected VL were less than half as likely to be 
“done” at Facility C when compared to Facility A (aOR 0.46, 95%CI 0.42–0.51). Expected 
VL at Facility C were also less likely to be included in the reported suppression proportion 
(aOR 0.74, 95%CI 0.69–0.78). Children under 15 years of age were more likely than men to 
have a routine VL done (aOR 1.89, 95%CI 1.45–2.48). Despite pregnant women being 
almost twice as likely as men to have a VL done within the routine window, their results were 
0.60 times as likely to be included in reported suppression proportions (aOR 1.90, 95%CI 
1.28–2.81 and aOR 0.60, 95%CI 0.47–0.77, respectively). The inclusion of duration on ART 
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in the model made no meaningful difference to the effect estimates in the model 
(Supplementary Table 1). 
Suppressed VL <400 copies/mL were slightly less likely to be included in reported 
suppression proportions (OR 0.70 95%CI 0.63–0.77). Actual VL suppression among all those 
VL done calculated using laboratory data was 82%, 87%, 89% and 91% at the 50, 200, 400 
and 1 000 copies/mL thresholds respectively, but reported suppression would have been 80%, 
86%, 88% and 89% at those same thresholds.  
Table 1: Patient characteristics, outcomes and adjusted odds ratios 
 Expected Done Reported 
 n (%) n (%) aOR (95%CI) n (%) aOR (95%CI) 
Facility A 7 129 (32) 6 313 (34) 1.00 3 815 (34) 1.00 
Facility B 5 916 (27) 5 130 (28) 0.84 (0.76–0.94) 3 181 (29) 1.01 (0.94–1.08) 
Facility C 8 946 (41) 7 007 (38) 0.46 (0.42–0.51) 4 104 (37) 0.74 (0.69–0.78) 
Men 6 097 (28) 5 012 (27) 1.00 3 138 (28) 1.00 
Non-pregnant women 15 011 (68) 12 649 (69) 1.17 (1.08–1.27) 7 546 (68) 0.96 (0.90–1.01) 
Pregnant women 275   (1) 246   (1) 1.90 (1.28–2.81) 107   (1) 0.60 (0.47–0.77) 
Children <15 yrs 608   (3) 543   (3) 1.89 (1.45–2.48) 309   (3) 0.99 (0.84–1.17) 
Years on ART 
   median (IQR) 




The reported VL suppression proportion <400 copies/mL from routine data of 89% differed 
by only 1% when including all VL results from the laboratory, despite only 60% of these VL 
contributing to reported suppression. This confirms that Khayelitsha is very close to 
achieving the third 90 among those with results available. However, taking into consideration 
the 16% of patients not tested, the proportion of patients with confirmed suppression <400 
copies/mL drops to 75% of those on ART and in care. This is worrying because it implies 
that even as we successfully increase ART coverage, the proportion of patients on ART who 
may be at risk of transmitting HIV remains between 10% and 25%. 
Reported completion proportions were low mostly due to failures to test patients (16%) and 
failures to capture VL results electronically (21%). The inclusion of electronically imported 
test results from laboratory systems in routine quarterly reports is currently being trialled in 
the Western Cape and would obviate the need for manual capturing of the results into PHCIS. 
However, the advantage of manual capture from the folder was that it allowed for indirect 
monitoring of other steps in the VL cascade, because the presence of a VL result in routine 
data implied successful progress through previous steps on the cascade. Specifically, it 
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implied that the result was available to the clinician at the next clinical assessment, as the 
clinician had to note it in the stationery for a clerk to capture it electronically. Importing 
results will improve the completeness of data in routine reports, but it will no longer be 
possible to make inferences about intermediate steps on the VL cascade from the routine 
data. Reassuringly, there was relatively little loss on the cascade between VL being done 
(step 2), filed (step 3) and noted (step 4), implying that results from VL tests that were done 
were usually available to clinicians at the next clinical assessment. 
Our results suggest that if electronic import of test results from laboratory systems is 
successfully implemented, the reported VL completion proportion will increase substantially 
but there will be little effect on the reported suppression proportion. Of note, this study only 
assessed whether clinicians noted the VL results in the folder and did not attempt to assess 
the effective use of VL results for clinical decision-making and further research in this 
important area is required. 
The variation in actual completion between facilities based on laboratory data suggests 
facility-specific challenges that require further investigation. The variation by pregnancy 
status and age category is expected, as clinical guidelines recommend more frequent testing 
for pregnant women and children. 
The underrepresentation of pregnant women in the reported suppression proportion may be 
due to increased mobility during pregnancy due to movement between integrated maternal-
ART clinics and routine ART clinics.(12) As discussed above, routine reports include only 
facility-specific naïve ART cohorts. However, this deserves further investigation as pregnant 
and breastfeeding women are vulnerable groups and viral suppression is critical to prevent 
vertical transmission.(13) Since the conclusion of this study, a separate routine quarterly 
report specifically for pregnant women was mandated by the national government. 
Overall, actual completion was relatively high, but more must be done to close the gaps and 
reach those patients not being tested, especially among men and non-pregnant women. Both 
suppressed and unsuppressed VL results inform patient management and clinical care. A 
suppressed VL may be used along with other indications to identify patients for recruitment 
to differentiated models of care, while an unsuppressed VL alerts a clinician to possible 
adherence challenges or drug resistance. We noted above that suppressed VL results were 
slightly less likely to successfully complete the VL cascade than unsuppressed VL results. 
This may suggest missed opportunities to recruit stable patients to differentiated models of 
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care, thereby unburdening the health facilities. Furthermore, it suggests that routine data may 
minimally underestimate the success of the ART programme. 
This study has limitations. Firstly, the study could not estimate the small proportion of 
requested VL that were not successfully processed by the laboratory. Secondly, in this study, 
in routine quarterly ART reports, and in the third 90 as defined by UNAIDS, the suppression 
proportion is calculated at a point in time using a single VL. By contrast, sustained 
suppression over time is required to reap the full benefits of ART and mitigate the risk of 
transmission. Thirdly, the results of this study may not be generalisable to other settings. 
Three large provincial facilities were included in this study and, while the main findings are 
likely to apply to other similar facilities in metropolitan areas of South Africa, some of the 
results may not be generalisable to settings outside of Khayelitsha. 
Strengths of this study include the assessment of routine data on >20 000 patients from 
multiple facilities including adults, pregnant women and children. This was made possible 
through close collaboration with the Provincial Department of Health, and the availability of 
harmonised data from different data sources in the health system provided by the PHDC. 
Conclusion 
Despite low reported VL completion, actual VL testing completion was high. The study 
confirmed the high levels of suppression that are routinely reported. More work is needed to 
reach the 16% of patients missed by routine testing. Most VL results were accessed and noted 
by clinicians, and further research is needed to assess how effectively these results are used in 
clinical decision-making. 
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Part D: Appendices to the Dissertation 
 
1. Only electronic data capture instruments were used. 
 
2. The requirement for informed patient consent was waived. 
 
3. The letter of approval from the UCT Human Research Ethics Committee is attached following 
this page. 
 
4. Instructions for Authors from the South African Medical Journal are attached following the 
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